Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been issued trade mark registration for RECCE® from Vietnam’s Intellectual Property Office.

The RECCE® mark has been classified under Class 5 with specifications: “Antibiotics”, “Antibiotics for human use”, and “Pharmaceutical preparations, namely mixed antibiotic preparations”.

With newly submitted patents pending in Vietnam, this trademark serves to strengthen Recce’s intellectual property portfolio and builds upon trademarks also already registered in the largest pharmaceutical markets in the world, including the United States, Israel, China, Australia, Japan, Hong Kong and Europe.

Recce CEO James Graham said, “We are thrilled to receive this newly awarded trademark in Vietnam, further strengthening Recce’s intellectual property portfolio in the Asia-Pacific region.

"This trademark is a welcomed advance and will support our ongoing fight against the global health threat of antibiotic-resistant superbugs.”

Recce is developing a new class of synthetic anti-infectives, to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Its anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:

RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms;

RECCE® 435 as an orally administered therapy for bacterial infections; and

Recce’s anti-infectives have the potential to overcome a challenge of all existing antibiotics to date — the hypercellular mutation of bacteria and viruses.

In 2020, Vietnam’s pharmaceutical market was valued at approximately US$10 billion, doubling in value since 2015; with the projected value reaching US$16.1 billion (A$25 billion) in 2026.

The company says that antibiotic resistance in Vietnam is amongst the highest in the world, where last-resort antibiotics, such as carbapenems or colistin, are being used frequently in large hospitals’ intensive care units.

This drives bacterial pathogens to develop resistance, eventually rendering them immune to common treatments.

Read the full article here: https://www.proactiveinvestors.com.au/companies/news/1025563/recce-pharmaceuticals-recce-issued-registered-trademark-in-vietnam-1025563.html?viewSource=TwitterAU

Recce Pharmaceuticals’ RECCE® issued registered trademark in Vietnam